Developments in mitogen-induced extracellular kinase 1 inhibitors and their use in the treatment of disease

Author： Krepinsky Joan   Wu Dongcheng   Ingram Alistair   Scholey James   Tang Damu  

Publisher： Informa Healthcare

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.12, Iss.12, 2002-12, pp. : 1795-1811

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Recent Developments in Cholinesterases Inhibitors for Alzheimer's Disease Treatment

By  

Current Medicinal Chemistry, Vol. 14, Iss. 25, 2007-10 ,pp. : 2654-2679

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting Mitogen-Activated Protein Kinase Phosphatase-1 (MKP-1): Structure-Based Design of MKP-1 Inhibitors and Upregulators

By  

Current Medicinal Chemistry, Vol. 19, Iss. 2, 2012-01 ,pp. : 163-173

Bentham Science Publishers

Access to resources Recommend Favorite

Glycogen Synthase Kinase-3 (GSK-3) Inhibitors for the Treatment of Alzheimer's Disease

By  

Current Pharmaceutical Design, Vol. 16, Iss. 25, 2010-08 ,pp. : 2790-2798

Bentham Science Publishers

Access to resources Recommend Favorite

Protein Kinase C Inhibitors: Rationale for Use and Potential in the Treatment of Bipolar Disorder

By Zarate Carlos A.   Manji Husseini K.  

CNS Drugs, Vol. 23, Iss. 7, 2009-07 ,pp. : 569-582

Adis International

Access to resources Recommend Favorite

Mitogen-activated protein kinase phosphatase-1 – a potential therapeutic target in metabolic disease

By Roth Flach Rachel J   Bennett Anton M  

Expert Opinion on Therapeutic Targets, Vol. 14, Iss. 12, 2010-12 ,pp. : 1323-1332

Informa Healthcare

Access to resources Recommend Favorite